Transplantation of mesenchymal stem cells and nucleus pulposus cells in a degenerative disc model in rabbits: a comparison of 2 cell types as potential candidates for disc regeneration

Feng, Ganjun; Zhao, Xianfeng; Líu, Hao; Zhang, Huina; Chen, Xiangjun; Shi, Rui; Liu, Xi; Zhao, Xiaodan; Zhang, Wenli; Wang, Beiyu

doi:10.3171/2010.11.spine10285

Cited by 79 publications

(57 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GAGs increased at 16 wks compared with controls, and disc regeneration was evidenced by real-time polymerase chain reaction (RT-PCR). No differences between MSCs and nucleous pulposus cells were observed, a finding supporting the hypothesis that MSCs are ideal substitutes for nucleous pulposus cells (93). Moreover, MSCs induce nucleous pulposus cells to suppress MMPs and inflammatory cytokine production in vitro (94).…”

Section: Cell Replacementsupporting

confidence: 66%

Biologic Treatment of Mild and Moderate Intervertebral Disc Degeneration

Vasiliadis

Pneumaticos

Evangelopoulos

et al. 2014

Mol Med

View full text Add to dashboard Cite

Disc degeneration is the most common cause of back pain in adults and has enormous socioeconomic implications. Conservative management is ineffective in most cases, and results of surgical treatment have not yet reached desirable standards. Biologic treatment options are an alternative to the above conventional management and have become very attractive in recent years. The present review highlights the currently available biologic treatment options in mild and moderate disc degeneration, where a potential for regeneration still exists. Biologic treatment options include protein-based and cell-based therapies. Proteinbased therapies involve administration of biologic factors into the intervertebral disc to enhance matrix synthesis, delay degeneration or impede inflammation. These factors can be delivered by an intradiscal injection, alone or in combination with cells or tissue scaffolds and by gene therapy. Cell-based therapies comprise treatment strategies that aim to either replace necrotic or apoptotic cells, or minimize cell death. Cell-based therapies are more appropriate in moderate stages of degenerated disc disease, when cell population is diminished; therefore, the effect of administration of growth factors would be insufficient. Although clinical application of biologic treatments is far from being an everyday practice, the existing studies demonstrate promising results that will allow the future design of more sophisticated methods of biologic intervention to treat intervertebral disc degeneration.

show abstract

Section: Cell Replacementsupporting

confidence: 66%

Biologic Treatment of Mild and Moderate Intervertebral Disc Degeneration

Vasiliadis

Pneumaticos

Evangelopoulos

et al. 2014

Mol Med

View full text Add to dashboard Cite

show abstract

“…1,2,10,16,20,22,25,[30][31][32][34][35][36][37][38]46,48,49,53,54,56,57,60,62,[64][65][66][67]69,73,83,90 The EuroDISC study, by Meisel and colleagues, 49 investigated the percutaneous transplantation of autologous disc chondrocytes. Following microdiscectomy, disc chondrocytes were harvested and expanded in vitro and were subsequently injected into the NP 3 months postoperatively.…”

Section: Discussionmentioning

confidence: 99%

“…Multiple preclinical animal studies have demonstrated the efficacy of intradiscally injected mesenchymal stem cells (MSCs) to induce disc regeneration. 1,2,16,18,20,21,25,[31][32][33][34]38,39,49,53,56,60,[64][65][66]69,73,83,87,90 Allogeneic mesenchymal progenitor cells (MPCs) are the earliest uncommitted clonogenic population of bone marrow stromal cells and have also successfully repaired the extracellular matrix following their injection into degenerative ovine discs. 25 Moreover, when ovine MPCs combined with the chondrogenic agent pentosan polysulfate (PPS) were embedded in a gelatin sponge and placed in a biodegradable cage that was implanted into the interbody space of ovine cervical spines, the cage became filled with a predominately cartilaginous matrix.…”

mentioning

confidence: 99%

Mesenchymal progenitor cells combined with pentosan polysulfate mediating disc regeneration at the time of microdiscectomy: a preliminary study in an ovine model

Oehme

Ghosh

Shimmon

et al. 2014

SPI

View full text Add to dashboard Cite

Object Following microdiscectomy, discs generally fail to undergo spontaneous regeneration and patients may experience chronic low-back pain and recurrent disc prolapse. In published studies, formulations of mesenchymal progenitor cells combined with pentosan polysulfate (MPCs+PPS) have been shown to regenerate disc tissue in animal models, suggesting that this approach may provide a useful adjunct to microdiscectomy. The goal of this preclinical laboratory study was to determine if the transplantation of MPCs+PPS, embedded in a gelatin/fibrin scaffold (SCAF), and transplanted into a defect created by microdiscectomy, could promote disc regeneration. Methods A standardized microdiscectomy procedure was performed in 18 ovine lumbar discs. The subsequent disc defects were randomized to receive either no treatment (NIL), SCAF only, or the MPC+PPS formulation added to SCAF (MPCs+PPS+SCAF). Necropsies were undertaken 6 months postoperatively and the spines analyzed radiologically (radiography and MRI), biochemically, and histologically. Results No adverse events occurred throughout the duration of the study. The MPC+PPS+SCAF group had significantly less reduction in disc height compared with SCAF-only and NIL groups (p < 0.05 and p < 0.01, respectively). Magnetic resonance imaging Pfirrmann scores in the MPC+PPS+SCAF group were significantly lower than those in the SCAF group (p = 0.0213). The chaotropic solvent extractability of proteoglycans from the nucleus pulposus of MPC+PPS+SCAF-treated discs was significantly higher than that from the SCAF-only discs (p = 0.0312), and using gel exclusion chromatography, extracts from MPC+PPS+SCAF-treated discs also contained a higher percentage of proteoglycan aggregates than the extracts from both other groups. Analysis of the histological sections showed that 66% (p > 0.05) of the MPC+PPS+SCAF-treated discs exhibited less degeneration than the NIL or SCAF discs. Conclusions These findings demonstrate the capacity of MPCs in combination with PPS, when embedded in a gelatin sponge and sealed with fibrin glue in a microdiscectomy defect, to restore disc height, disc morphology, and nucleus pulposus proteoglycan content.

show abstract

“…the transplantation of nP and mesenchymal stem cells is proven to be effective in a rabbit model of iVD degeneration (5). Disc regeneration was confirmed regarding the elevation of the disc height, signal intensities on MR imaging, and histological assessment.…”

Section: Cell and Tissue Transplantationmentioning

confidence: 86%